ArticleBMC cardiovascular disorders2025
Association between the aggregate index of systemic inflammation and 28- or 365-day mortality in acute myocardial infarction patients: insights from the MIMIC-IV database.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Machine Learning-Based Comparative Analysis of Blood Cell-Derived Inflammatory Indices for Predicting MAFLD and Liver Fibrosis: Evidence From NHANES 2017-2020.Journal of clinical laboratory analysis · 2026Article
- Prognostic value of the aggregate index of systemic inflammation in palliative care patients.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSystemic inflammation plays a key role in acute myocardial infarction (AMI). The Aggregate Index of Systemic Inflammation (AISI), a composite measure of neutrophils, monocytes, platelets, and lymphocytes, may offer a more comprehensive assessment of inflammation than single biomarkers. However, its association with short- and long-term mortality in AMI patients remains underexplored.
methodsThis retrospective study analyzed data from 969 AMI patients in the Medical Information Mart for Intensive Care(MIMIC) -IV database, stratified by AISI levels into tertiles. Cox regression and Kaplan-Meier survival analyses assessed the relationship between AISI and mortality. Subgroup analyses examined age, gender, and comorbidity effects, and the predictive value of AISI was evaluated using Receiver Operating Characteristic(ROC) curves.
resultThis study enrolled 969 patients with AMI, stratified into group1(low), group2(medium), and group3(high) tertiles. The group3 exhibited significantly higher 28-day mortality (18.6% vs. 5.6% in low/medium groups) and 365-day mortality (27.2% vs. 13.3% in the low group) (both P < 0.001). Survival analysis demonstrated an inverse correlation between AISI levels and survival probability (P < 0.001). Restricted cubic spline(RCS) models revealed a nonlinear association between AISI and mortality (28-day: likelihood ratio test P = 0.001; 365-day: P = 0.002). Multivariable Cox regression confirmed a dose-response relationship between AISI tertiles and mortality risk (trend P < 0.001 for both endpoints). Subgroup analyses highlighted greater sensitivity to AISI in female patients (28-day: interaction P = 0.041; 365-day: P = 0.011), with ROC curve analysis showing enhanced predictive performance in females (28-day AUC: 0.759 vs. 0.669, P = 0.019; 365-day AUC: 0.760 vs. 0.730, P = 0.038).
conclusionIn this study, AISI exhibited a nonlinear association with 28-day and 365-day mortality in AMI patients. Higher AISI levels were significantly linked to increased mortality risk. Notably, female patients showed greater sensitivity to elevated AISI, suggesting its potential value in risk stratification and clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.